Skip to main content

Table 1 Baseline characteristics

From: Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission

 

Pre-Intervention N = 76

Post-Intervention N = 170

p-value

Age, mean ± standard deviation

58 ± 16.2

61 ± 17

0.20

Male gender

38 (50)

78 (46)

0.65

Race/ethnicity

 Black/African American

71 (93)

151 (88)

0.37

 White

3 (4)

10 (6)

0.76

 Asian

0 (0)

2 (1)

> 0.99

 Other

0 (0)

1 (0.6)

> 0.99

 Unknown

0 (0)

4 (2)

0.31

 Hispanic/Latino

0 (0)

2 (1)

> 0.99

Hypertension

48 (63)

110 (64)

0.93

Cardiovascular disease

20 (26)

55 (32)

0.44

Diabetes

15 (20)

62 (36)

0.01

Asthma

10 (13)

21 (12)

0.86

Chronic or end stage renal disease

9 (12)

19 (11)

0.87

Immunodeficiencya

8 (10)

10 (6)

0.30

COPD

7 (9)

16 (9)

0.97

Obstructive sleep apnea

6 (8)

9 (5)

0.61

HIV

4 (5)

2 (1)

0.07

Bronchiectasis

0 (0)

1 (0.6)

> 0.99

Baseline O2 requirement

 Room air

23 (30)

42 (25)

0.45

 Nasal cannula

46 (60)

103 (60)

0.99

 High flow nasal cannula

4 (5)

17 (10)

0.32

 Non-rebreather

1 (1)

1 (0.6)

0.52

 Mechanical ventilation

2 (3)

7 (4)

0.84

ICU admission within first 24 h

21 (28)

51 (30)

0.82

ICU admission at any point

31 (41)

71 (42)

0.99

Mechanical ventilation within first 24 h

18 (24)

18 (11)

0.01

Mechanical ventilation at any point

24 (36)

29 (17)

0.02

Fever at time of antibiotic initiation

19 (25)

93 (55)

< 0.001

Leukocytosis at time of antibiotic initiation

5 (7)

41 (24)

0.002

RBVP obtained

67 (88)

154 (91)

0.72

 Positive RBVP

1 (1)

3 (2)

> 0.99

Legionella urinary antigen obtained

59 (78)

141 (82)

0.42

 Positive Legionella

0 (0)

0 (0)

Streptococcus pneumoniae urinary antigen obtained

58 (76)

141 (82)

0.30

 Positive Streptococcus pneumoniae

0 (0)

2 (1.4)

> 0.99

Respiratory cultures obtained

20 (26)

51 (30)

0.70

 Positive respiratory culture

1 (5)

4 (8)

> 0.99

Blood cultures obtained

60 (79)

141 (82)

0.57

MRSA swab obtained

42 (55)

125 (74)

0.007

 Positive MRSA Swab

1 (2)

6 (8)

0.70

Antibioticsb

 Azithromycin

69 (91)

110 (65)

< 0.001

 Doxycycline

6 (8)

19 (11)

0.60

 Ceftriaxone

64 (84)

112 (66)

0.005

 Cefdinir

50 (66)

72 (42)

0.001

 Levofloxacin

2 (3)

1 (0.6)

0.22

 Cefepime

26 (34)

47 (28)

0.40

 Vancomycin

32 (42)

50 (29)

0.07

 Amoxicillin-clavulanate or Ampicillin-sulbactam

4 (5)

4 (2)

0.26

 Metronidazole

9 (12)

15 (9)

0.60

 Other

6 (8)

7 (4)

> 0.99

Antivirals (COVID-19 Directed Therapy)

 HCQc

56 (74)

43 (25)

< 0.001

 Tocilizumab

17 (22)

41 (24)

0.90

 Remdesivird

24 (32)

48 (28)

0.70

 None

11 (14)

67 (39)

< 0.001

  1. a Including transplant patients currently on immunosuppression or patients with malignancy and received chemotherapy or radiation within the past 3 months or Acquired Immunodeficiency Syndrome (AIDS)
  2. bAntibiotics initiated empirically for CABP within the first 48 h
  3. c Given alone, or in combination with LPV/r or RBV
  4. d Includes compassionate use or trial Remdesivir
  5. Abbreviations: HCQ hydroxychloroquine, LPV/r lopinavir/ritonavir, RBV: ribavirin
  6. All data are n (%), unless otherwise noted